Literature DB >> 9419364

Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity.

L B Nicholson1, H Waldner, A M Carrizosa, A Sette, M Collins, V K Kuchroo.   

Abstract

Productive engagement of T cell receptors (TCRs) by cognate ligand (major histocompatibility complex plus peptide) leads to proliferation, differentiation, and the elaboration of effector functions. Altered peptides generated by single amino acid substitutions in the antigenic peptide have diverse effects on the outcome of the T cell response. We have generated an altered peptide (Q144) from an autoantigenic peptide of myelin proteolipid protein 139-151 by a single amino acid substitution (from tryptophan to glutamine) in the primary TCR contact at position 144 that is capable of inducing CD4(+) T cell responses in H-2(s) mice. By using a Q144-specific T cell clone (Q1.1B6), we see a hierarchy in T cell proliferation and cytokine production with various position 144 substituted peptides and have identified a peptide (L144) that hyperstimulates this T cell clone. In contrast to Q144, L144 induces maximal proliferation at 7 logs lower antigen concentration, induces greater cell death at higher antigen dose, and induces the secretion of cytokines not detected following stimulation with the cognate ligand. This heteroclitic T cell response associated with changes in cytokine profile was observed with several other T cell clones of different specificities. The L144 peptide also induces costimulation independent proliferation and cytokine production from the Q1.1B6 T cell clone. We describe this as a superagonist response. Such responses may have a role in the initiation of autoimmunity by promoting a proinflammatory environment following ligation of a cross-reactive TCR on autoreactive T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9419364      PMCID: PMC18196          DOI: 10.1073/pnas.95.1.264

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Authors:  R H Schwartz
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

2.  The T-cell-receptor repertoire in the synovial fluid of a patient with rheumatoid arthritis is polyclonal.

Authors:  Y Uematsu; H Wege; A Straus; M Ott; W Bannwarth; J Lanchbury; G Panayi; M Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

3.  Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor.

Authors:  M T De Magistris; J Alexander; M Coggeshall; A Altman; F C Gaeta; H M Grey; A Sette
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

4.  Characterization of the specificity of peptide binding to four DR haplotypes.

Authors:  D O'Sullivan; J Sidney; E Appella; L Walker; L Phillips; S M Colón; C Miles; R W Chesnut; A Sette
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

5.  T cell receptor alpha-chain defines the antigen specificity of antigen-specific suppressor factor but does not impart genetic restriction.

Authors:  R M O'Hara; M C Byrne; V K Kuchroo; A Nagelin; M J Whitters; S Jayaraman; S L Henderson; M E Dorf; M Collins
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

Review 6.  Manipulation of the Th1/Th2 balance in autoimmune disease.

Authors:  L B Nicholson; V K Kuchroo
Journal:  Curr Opin Immunol       Date:  1996-12       Impact factor: 7.486

7.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand.

Authors:  B D Evavold; P M Allen
Journal:  Science       Date:  1991-05-31       Impact factor: 47.728

8.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo.

Authors:  C Pfeiffer; J Stein; S Southwood; H Ketelaar; A Sette; K Bottomly
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

9.  Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.

Authors:  M H Wauben; C J Boog; R van der Zee; I Joosten; A Schlief; W van Eden
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

10.  Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling.

Authors:  L Racioppi; F Ronchese; L A Matis; R N Germain
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  11 in total

1.  4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Authors:  Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard L Kaufman
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

Review 2.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

3.  Dynamic Mitochondrial Migratory Features Associated with Calcium Responses during T Cell Antigen Recognition.

Authors:  Luye He; Andrew D Raddatz; Fangyuan Zhou; Hyundoo Hwang; Melissa L Kemp; Hang Lu
Journal:  J Immunol       Date:  2019-06-14       Impact factor: 5.422

4.  Human leucocyte antigen-A2 restricted and Mycobacterium tuberculosis 19-kDa antigen-specific CD8+ T-cell responses are oligoclonal and exhibit a T-cell cytotoxic type 2 response cytokine-secretion pattern.

Authors:  H Höhn; C Kortsik; K Nilges; A Necker; K Freitag; G Tully; C Neukirch; M J Maeurer
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

Review 5.  Cross-reactivity of T cells and its role in the immune system.

Authors:  Galina Petrova; Andrea Ferrante; Jack Gorski
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

6.  Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease.

Authors:  E Hauben; E Agranov; A Gothilf; U Nevo; A Cohen; I Smirnov; L Steinman; M Schwartz
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

7.  Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Authors:  Melita Irving; Vincent Zoete; Michael Hebeisen; Daphné Schmid; Petra Baumgartner; Philippe Guillaume; Pedro Romero; Daniel Speiser; Immanuel Luescher; Nathalie Rufer; Olivier Michielin
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

Review 8.  Transgenic mouse models of multiple sclerosis.

Authors:  Tanja Scheikl; Béatrice Pignolet; Lennart T Mars; Roland S Liblau
Journal:  Cell Mol Life Sci       Date:  2010-08-17       Impact factor: 9.261

9.  NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease.

Authors:  Lori Blanchfield; Joseph J Sabatino; Laurel Lawrence; Brian D Evavold
Journal:  J Immunol       Date:  2017-09-08       Impact factor: 5.422

10.  Reduced self-reactivity of an autoreactive T cell after activation with cross-reactive non-self-ligand.

Authors:  Markus Munder; Estelle Bettelli; Laurent Monney; Jacqueline M Slavik; Lindsay B Nicholson; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2002-11-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.